

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Nancy J. Harper, et al. : Examiner: Oh,Taylor V.
APPLICATION NO.: Not Yet Known : Group Art Unit: 1624
FILING DATE: Concurrently Herewith :
TITLE: SERTRALINE ORAL CONCENTRATE :

Commissioner for Patents
P.O. Box 1450
Alexandria, VA. 22313-1450

Sir:

PRELIMINARY AMENDMENT

Prior to examination on the merits, please amend the application as follows:

IN THE SPECIFICATION:

Page 1, between lines 3 and 4, insert the following text:

--This application is a continuation of Ser. No. 09/417,175, filed Oct. 11, 1999,
which claims the benefit of Ser. No. 60/104,024, filed Oct. 13, 1998.--


REMARKS

The subject application is a continuation of Ser. No. 09/417,175, filed Oct. 11, 1999, which claims the benefit of provisional Ser. No. 60/104,024, filed Oct. 13, 1998, and is filed to pursue the invention of claims 1-13. Applicant has inserted priority information on page 1 for the present application as required by 37 C.F.R. § 1.78.

If a telephone interview is deemed to be helpful to expedite the prosecution of the subject application, the Examiner is invited to contact applicant's undersigned attorney at the telephone number provided.

The Commissioner is hereby authorized to charge any fees required under 37 C.F.R. §§1.16 and 1.17, or to credit any overpayment, to Deposit Account No. 16-1445.

Respectfully submitted,


A. David Joran
Attorney for Applicant(s)
Reg. No. 37,858

Date: February 3, 2004

Pfizer Inc
Patent Department
150 East 42nd Street – 5th Floor
New York, NY 10017-5755
(212) 733-3381